Tumour Virus Research最新文献

{"title":"Development and evaluation of an online continuing education course to increase healthcare provider self-efficacy to make strong HPV vaccine recommendations to East African immigrant families","authors":"SarahAnn M. McFadden ,&nbsp;Linda K. Ko ,&nbsp;Megha Shankar ,&nbsp;Anisa Ibrahim ,&nbsp;Debra Berliner ,&nbsp;John Lin ,&nbsp;Farah B. Mohamed ,&nbsp;Fanaye Amsalu ,&nbsp;Ahmed A. Ali ,&nbsp;Sou Hyun Jang ,&nbsp;Rachel L. Winer","doi":"10.1016/j.tvr.2021.200214","DOIUrl":"10.1016/j.tvr.2021.200214","url":null,"abstract":"<div><h3>Objective</h3><p>To develop and evaluate an online continuing education (CE) course designed to improve healthcare provider self-efficacy to make strong adolescent HPV vaccine recommendations to East African immigrant families.</p></div><div><h3>Methods</h3><p>Focus groups with providers and East African immigrant mothers informed course development. Providers serving East African immigrant families were recruited to view the course and complete pre-/post-test and two-month follow-up surveys. Pre-/post differences were compared with paired t-tests.</p></div><div><h3>Results</h3><p>202 providers completed the course and pre-/post-test; 158 (78%) completed two-month follow-up. Confidence to make strong HPV vaccine recommendations to East African families increased from 68% pre-test to 98% post-test. Confidence to address common parental concerns also increased: safety, 54% pre-test, 92% post-test; fertility, 55% pre-test, 90% post-test; child too young, 68% pre-test, 92% post-test; and pork gelatin in vaccine manufacturing, 38% pre-test, 90% post-test. Two-month follow-up scores remained high (97% for overall confidence, 94%–97% for addressing parental concerns). All pre-/post-test and pre-test/two-month follow-up comparisons were statistically significant (p &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>The online CE course focused on culturally appropriate strategies for making strong recommendations and addressing specific parental concerns was effective for increasing provider self-efficacy to recommend HPV vaccination to East African families. Similar courses could be tailored to other priority populations.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200214"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25417755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing immunity for therapy in human papillomavirus driven cancers","authors":"Peter L. Stern","doi":"10.1016/j.tvr.2021.200212","DOIUrl":"10.1016/j.tvr.2021.200212","url":null,"abstract":"<div><p>In persistent high-risk HPV infection, viral gene expression can trigger some important early changes to immune capabilities which act to protect the lesion from immune attack and subsequently promote its growth and ability for sustained immune escape. This includes immune checkpoint-inhibitor ligand expression (e.g. PD-L1) by tumour or associated immune cells that can block any anti-tumour T-cell effectors. While there are encouraging signs of efficacy for cancer immunotherapies including with immune checkpoint inhibitors, therapeutic vaccines and adoptive cell therapies, overall response and survival rates remain relatively low. HPV oncogene vaccination has shown some useful efficacy in treatment of patients with high-grade lesions but was unable to control later stage cancers. To maximally exploit anti-tumour immune responses, the suppressive factors associated with HPV carcinogenesis must be countered. Importantly, a combination of chemotherapy, reducing immunosuppressive myeloid cells, with therapeutic HPV vaccination significantly improves impact on cancer treatment. Many clinical trials are investigating checkpoint inhibitor treatments in HPV associated cancers but response rates are limited; combination with vaccination is being tested. Further investigation of how chemo- and/or radio-therapy can influence the recovery of effective anti-tumour immunity is warranted. Understanding how to optimally deploy and sequence conventional and immunotherapies is the challenge.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200212"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?","authors":"Megan A. Smith ,&nbsp;Karen Winch ,&nbsp;Karen Canfell ,&nbsp;Julia ML. Brotherton","doi":"10.1016/j.tvr.2021.200216","DOIUrl":"10.1016/j.tvr.2021.200216","url":null,"abstract":"<div><h3>Background</h3><p>Initially, three-dose schedules were recommended for vaccines against human papillomavirus (HPV); subsequently recommendations have been updated to a schedule of two doses delivered at least six (minimum five) months apart for those aged &lt;15 years at dose 1. We aimed to re-estimate effective HPV vaccination coverage in Australia, considering reduced-dose schedules and possible one-dose effectiveness. We also aimed to identify which of the three school visits was most commonly missed amongst two-dose only recipients, to inform optimal timing of visits.</p></div><div><h3>Methods</h3><p>National vaccination register data were used to estimate: i) vaccination coverage at December 2017, either with a complete course (three or two sufficiently-spaced doses (&gt;151 days apart)), or at least one dose; ii) for each birth cohort offered vaccination, the percentage of the initially targeted cohort with a complete course, or at least one dose (reflecting uptake at the time the vaccine was offered); and iii) among two-dose only recipients, the percentage who missed each of three school visits.</p></div><div><h3>Results</h3><p>Including those with two sufficiently-spaced doses increased end-2017 coverage by 1.3–2.8% points in those vaccinated at school. Including those with at least one dose increased coverage further, by 6.5–9.5% points, mostly due to including those receiving multiple too-closely-spaced doses. One-dose coverage reached 90.9% and 86.9% in females and males respectively born in 2002.</p><p>Among those vaccinated at school who received only two doses, it was much more common to miss the first (31.0% females; 32.5% males) or the third visit in the school year (54.6% females; 48.6% males) than the second (14.1% females; 18.8% males).</p></div><div><h3>Conclusions</h3><p>Including those with two sufficiently-spaced doses has a very modest impact on HPV vaccine coverage in Australia. If receiving at least one dose offers substantial protection, these data suggest that the school-based program is now achieving close to 90% coverage on this measure.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200216"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38802429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus E6 and E7: What remains?","authors":"Arushi Vats ,&nbsp;Oscar Trejo-Cerro ,&nbsp;Miranda Thomas,&nbsp;Lawrence Banks","doi":"10.1016/j.tvr.2021.200213","DOIUrl":"10.1016/j.tvr.2021.200213","url":null,"abstract":"<div><p>Decades of research on the human papillomavirus oncogenes, E6 and E7, have given us huge amounts of data on their expression, functions and structures. We know much about the very many cellular proteins and pathways that they influence in one way or another. However, much of this information is quite discrete, referring to one activity examined under one condition. It is now time to join the dots to try to understand a larger picture: how, where and when do all these interactions occur... and why? Examining these questions will also show how many of the yet obscure cellular processes work together for cellular and tissue homeostasis in health and disease.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200213"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25476990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings [Papillomavirus Res. 10 (2020) 100206]","authors":"Sam Ratnam ,&nbsp;Dan Jang ,&nbsp;Laura Gilbert ,&nbsp;Reza Alaghehbandan ,&nbsp;Miranda Schell ,&nbsp;Rob Needle ,&nbsp;Anne Ecobichon-Morris ,&nbsp;Peizhong Peter Wang ,&nbsp;Mozibur Rahman ,&nbsp;Dustin Costescu ,&nbsp;Laurie Elit ,&nbsp;George Zahariadis ,&nbsp;Max Chernesky","doi":"10.1016/j.tvr.2021.200215","DOIUrl":"10.1016/j.tvr.2021.200215","url":null,"abstract":"","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200215"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25496077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Welcome to Tumour Virus Research","authors":"Peter L. Stern,&nbsp;Lawrence Banks","doi":"10.1016/j.tvr.2021.200211","DOIUrl":"10.1016/j.tvr.2021.200211","url":null,"abstract":"","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200211"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}